Geovax to raise approximately $5.0 million of gross proceeds in offering priced at-the-market

Atlanta, ga, aug. 28, 2024 (globe newswire) -- geovax labs, inc. (nasdaq: govx), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the company's common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under nasdaq rules.
GOVX Ratings Summary
GOVX Quant Ranking